Drug #1: ERX-963
Status: In June 2019 Expansion commenced a Phase 1 trial in 12 adult-onset myotonic dystrophy patients.
Drug #2: Small molecule RNA inhibitor
Company Website with description of approach
Video from 2018 MDF Conference
January 3, 2018 Press Release on Expansion's launch
Publication of preclinical tests
September 14, 2019 Presentation at Myotonic Conferenct (1:00)